Ethanolic stem bark extract of terminalia ivorensis A. Chev. protects against potassium dichromate–induced nephrotoxicity in rats. by Aliu, Moomin et al.
MOOMIN, A., MENSAH, K.B., FORKUO, A., ADU-GYAMFI, P.K.T. and ANSAH, C. 2020. Ethanolic stem bark extract of 
terminalia ivorensis A. Chev. protects against potassium dichromate-induced nephrotoxicity in rats. Scientific African 
[online], 8, article number e00410. Available from: https://doi.org/10.1016/j.sciaf.2020.e00410 
Ethanolic stem bark extract of terminalia 
ivorensis A. Chev. protects against potassium 
dichromate-induced nephrotoxicity in rats. 
MOOMIN, A., MENSAH, K.B., FORKUO, A., ADU-GYAMFI, P.K.T. and 
ANSAH, C.  
2020 
This document was downloaded from 
https://openair.rgu.ac.uk 
© 2020 Published by Elsevier B.V. on behalf of African Institute of Mathematical Sciences. 
Scientific African 8 (2020) e00410 
Contents lists available at ScienceDirect 
Scientific African 
journal homepage: www.elsevier.com/locate/sciaf 
Ethanolic stem bark extract of Terminalia ivorensis A. Chev. 
protects against potassium dichromate–induced 
nephrotoxicity in rats 
Aliu Moomin a , c , Kwesi Boadu Mensah a , ∗, Arnold Donkor Forkuo a , 
Paa Kofi Tawiah Adu-Gyamfib , Charles Ansah a 
a Dept of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Science, Kwame Nkrumah University of 
Science and Technology, Kumasi, Ghana 
b Department of Nursing and Midwifery, Faculty of Health and Allied Sciences, Pentecost University College Accra, Accra, Ghana 
c School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen,UK 
a r t i c l e i n f o 
Article history: 
Received 3 December 2019 
Revised 20 February 2020 
Accepted 22 April 2020 
Keywords: 
Nephroprotection 
Oxidative stress 
Glutathione 
Superoxide dismutase 
Traditional medicine 
a b s t r a c t 
Objective: The plant Terminalia ivorensis is used in traditional medicine as a diuretic and 
in the management of renal failure. We reported previously that the ethanol stem bark 
extract of the plant protects against gentamicin-induced renal and hepatic damage in rats. 
To further elucidate the mechanism of its renoprotective activity, we studied the effects 
of the extract on Potassium dichromate–induced nephrotoxicity in rats . The present study 
assessed the effectiveness of the ethanol stem bark extract of Terminalia ivorensis - against 
renal oxidative injury evoked by potassium dichromate. 
Methods: Adult Sprague Dawley rats pre-treated with (100–1000 mg/kg p.o . bwt) of Termi- 
nalia ivorensis extract for 5 days were challenged with a single dose of Potassium dichro- 
mate (20 mg/kg Sc ) in the neck region on the 4th day. On the sixth day, renal function and 
markers of oxidative injury were assessed. 
Results: Terminalia ivorensis (30 0–10 0 0 mg/kg p.o ) pre-treatment dose dependently pre- 
vented decreases in urine output in rats challenged with a nephrotoxic dose of Potassium 
Dichromate. The extract also protected the rats against Potassium dichromate-induced rise 
in serum electrolytes, urea and creatinine. Furthermore, it dose dependently prevented 
Potassium dichromate-induced decrease in renal glutathione (GSH) levels whereas tissue 
oxidative enzymes Superoxide dismutase (SOD) and catalase were protected from damage. 
Markers of lipid peroxidation such as level of renal Malondialdehyde (MDA) and myeloper- 
oxidase (MPO) also decreased dose dependently when compare with Potassium dichromate 
treated groups. The extract also protected the histomorphology of the kidney against Potas- 
sium dichromate induced damage. 
Conclusion: The ethanol stem bark extract of Terminalia ivorensis protects kidney against 
Potassium dichromate-induced renal damage. 
© 2020 Published by Elsevier B.V. on behalf of African Institute of Mathematical Sciences 
/ Next Einstein Initiative. 
This is an open access article under the CC BY-NC-ND license. 
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 Introduction 
Renal failure due to kidney damage and associated renal insufficiency is an important adverse effect of common thera-
peutic agents such as non-steroidal anti-inflammatory drugs (NSAIDS) and antibiotics such as aminoglycosides, vancomycin
and polyenes [1–3] which limits their clinical usefulness. Furthermore, kidney diseases appear to increase globally [4] and
more people now require either transplant or frequent dialysis to improve their quality of life. Drug-induced nephropathy
and renal failure secondary to pre-existing medical conditions place enormous economic burden on the individual and na-
tional health care systems. In Ghana the cost of dialysis per year is above $90 0 0 and the cost of a kidney transplant is
about $60 0 0 [5] . The search for new nephroprotective agents that enhance renal tissue regeneration will reduce the cost
of managing renal diseases and give clinicians greater leverage in their choice of medicines for the management of renal
diseases. 
The tropical plant, Terminalia ivorensis is reported to be useful in the treatment of ulcers, cuts, sores, wounds, general
body pains, hemorrhoids, diuresis, malaria and yellow fever [6–10] Because of its purported anti-inflammatory activity in
traditional medicine [11] , we had reasoned that its effects on the kidney may be similar to that of NSAIDS. However, recent
work in our laboratory showed that the ethanol extract of the plant protected rats against gentamycin-induced renal damage
[12] . Furthermore, the plant extract stimulated renal tissue regeneration following damage induced by gentamycin. As to
whether the extract has the potential to protect against other nephrotoxicants is currently unknown. The objective of the
present study was to assess the potential of the ethanol extract of the stem bark of Terminalia ivorensis to reverse renal
damage caused by Potassium dichromate, a nephrotoxic hexavalent chromium that induces oxidative stress and cytotoxicity
in renal cells [13–15] 
Materials and methods 
Preparation of plant material 
The stem bark of Terminalia ivorensis was collected from Asakraka Kwahu in the Eastern region of Ghana in September
2014. The samples were authenticated at the Department of Herbal Medicine, Kwame Nkrumah University of Science and
Technology, Kumasi, Ghana, and a specimen with voucher number FP/095/10 deposited at the Department’s herbarium. The
harvested stem bark was washed, air dried and powdered using a hammer mill. Ethanol (70%) was used to extract the
sample by adding 5.0 L to every 1 kg of the powdered sample and the mixture allowed to stand for 72 h. The supernatant
was filtered and evaporated using a Rota evaporator at a temperature of 60 ᴼ C in vacuo. The wet mass was then oven dried
at 55 ᴼ C and the yield obtained was 24.3% w/w. The sample was kept in refrigerator and routinely reconstituted in distilled
water for oral administration when needed to rats. 
Chemicals 
Ethanol, glacial acetic acid, n-butanol, hydrogen peroxide and Tris – HCl, were obtained from BDH chemicals Ltd, Poole,
England. Phenazine methosulphate 5,5 ′ – dithiobis-(2-nitrobenzoic acid), o-dianisidine, nitroblue tetrazolium (NBT) reduced 
nicotinamide adenine dinucleotide (NADH), thiobarbituric acid (TBA), trichloroacetic acid (TCA) and Potassium dichromate 
were obtained from Sigma – Aldrich chemicals Co., St Louis, Missouri, USA. 
Phytochemical screening 
Qualitative phytochemical screening for bioactive molecules of the crude stem bark extract was carried-out based on
methods described elsewhere by Sofowora [16] . 
HPLC fingerprinting 
Varying concentrations of extracts (0.1 – 10 mg/ml) were prepared for HPLC analysis. A modular Shimadzu LC-20 system
consisting of a LC-20AD pump, a CTO-20AC column oven, an SPD-M20A UV-DAD detector, a CBM-20A interface and a LC-
20AT Workstation was utilized. An LC-18 column (250 mm x 4.6 mm i.d. x 5 mm) from Supelco (Bellefonte, USA) was
employed, at 30 0 C. Separations were done in the isocratic mode, using acetonitrile:water (40:60; v/v) at a flow rate of
1 mL min-1; with an injection volume of 20 μL; UV detection was at 350 nm. 
Experimental animals 
Sprague – Dawley rats (200 – 240 g) of both sexes obtained from the Animal house of the Department of Pharmacology,
KNUST were acclimatized on a 12-hour light and dark cycle for one week before the experiments. They were kept in stan-
dard aluminum laboratory cages (34 × 47 × 18 cm) with fine wood shavings as bedding and had free access to feed and
water ad libitum . All experimental procedures were in accordance with the Declaration of Helsinki and the Guiding Principles
in the Care and Use of Animals and were subsequently approved by departmental ethics committee (PCOL/ETH/122015). 
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 Acute toxicity study of ethanol extract of Terminalia ivorensis in rats 
The method used for the acute study was as described elsewhere [17] . Thirty Sprague – Dawley rats (200 – 240g) of both
sexes were grouped into six ( n = 5). Group I (control) received vehicle (distilled water) only. Groups II – VI received 100,
50 0, 10 0 0, 30 0 0 and 50 0 0 mg/kg of extract orally by gavage respectively. The animals were observed every 30 min over a
24-hour period for general behavioral, physiological changes including CNS stimulation and depression, autonomic changes
and lethality. The animals were further observed for 14 days for possible latent toxicity of the extract. 
Effect of Terminalia ivorensis extract on Potassium dichromate – induced nephrotoxicity 
The method used was as described previously by Aslam et al. [18] . Thirty (30) Sprague – Dawley rats (180 – 240 g) of
both sexes were weighed and placed into five groups ( n = 6). They were left to acclimatize for one week with fresh water
and feed ad libitum . 
The groups were subsequently treated initially as follows: 
• Group I (control): received distilled water (1 mL/kg/day orally) for 5 days. 
• Group II: received distilled water (1 mL/kg/day orally) for 5 days. 
• Group III: received extract (100 mg/kg/day orally) for 5 days. 
• Group IV: received extract (300 mg/kg/day orally) for 5 days. 
• Group V: received extract (10 0 0 mg/kg/day orally) for 5 days. 
All the groups except group I received a single dose of Potassium dichromate (1 ml, 20 mg/kg s.c ) on day 4 in the
cervical region. On the 5th day, all animals were placed in metabolic cages for 24 – hour urine collection. This was followed
by weighing and collection of blood samples from the retro – orbital venous plexus of all animals on the sixth day for the
estimation of serum electrolytes and biochemistry. All animals were then sacrificed by cervical dislocation and their kidneys
were removed, washed with normal saline, weighed and the right kidney preserved for histopathological studies. The left
kidney was used for the preparation of post–mitochondrial supernatant. 
Estimation of serum biochemical parameters 
For the estimation of urea, creatinine and electrolytes collected blood samples were centrifuged at 50 0 0 r.p.m for 10 min.
Biotecnica BT 30 0 0 Targa chemistry analyzer and Flexor Junior Auto analyzer were used for the assessment of renal bio-
chemistry and electrolytes respectively [18] . 
Preparation of tissue homogenate and estimation of biomarkers of oxidative stress 
Left kidneys were cleaned free of extraneous material and immediately perfused with ice – cold saline (0.85% sodium
chloride), homogenized in chilled phosphate buffer (0.1 M, pH 7.4) containing KCl (1.17%) with Potter-Elvehjem homogenizer
(Ultra-Turrax T25, Janke & Kunkel IKA- Labortechnik, Staufen, Germany). The homogenate was filtered through a clean mate-
rial and centrifuged with Hettich-zentrifugen (Micro 220R, Germany) at 800 X g for 5 min at 4 ᴼ  C to separate the debris. The
supernatant obtained was again centrifuged at 50 0 0 rpm for 30 min at 4 ᴼ C to obtain the post – mitochondrial supernatant
(PMS), which was used as the enzyme source for the biochemical estimations. All the assays were completed within 24 h of
animal sacrifice (Khan & Sultana 2005). Methods described elsewhere were used to assay reduced glutathione, superoxide
dismutase, catalase, lipid peroxidation and myeloperoxidase activity respectively [19–23] . 
Histopathological analysis 
Right kidneys of rats were fixed in 10 % neutral buffered formalin solution for histopathological processing. Sections
of the kidneys were stained with hemotoxylin and eosin, and observed under a Leica DM 750 microscope (ICC50 HD,
JosHansen, Germany) using a X400 magnification. 
Statistical analysis 
GraphPad Prism 6.0 was used and differences between groups were analyzed using One – Way Analysis of Variance
(ANOVA) followed by Sidak’s multiple comparison test. All results were presented as mean ± SEM. 
Results 
Phytochemistry and HPLC analysis 
Phytochemical analysis indicated the presences of flavonoids, terpenoids, alkaloids, condensed tannins, Saponins, cardiac
glycosides, anthraquinones and steroids. HPLC analysis showed 3 major compounds at different retention (Figure S1). 
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Fig. 1. Effects of Potassium dichromate (20 mg/kg) and Terminanlia ivorensis extract (TIE) (10 0, 30 0, 10 0 0 mg/kg) on 24 – hour urine output. ∗∗p < 0.01, 
∗∗∗p < 0.001 as compared to the control group (one-way ANOVA followed by Sidak’s post hoc test) and ᵗᵗᵗ p < 0.001 as compared to K 2 Cr 2 O 7 group (one-way 
ANOVA followed by Sidak’s post hoc test). 
Table 1 
Effects of extract of Terminalia ivorensis and Potassium dichromate on serum biochemistry and electrolytes in rats. 
Treatment Creatinine ( μmol/L) Urea (mmol/L) Sodium (m/L) Potassium (m/L) Chloride (m/L) 
Control: distilled 10 ml/kg 27.83 ± 1.85 5.09 ± 0.11 121.70 ± 3.25 12.85 ± 0.48 84.50 ± 2.35 
K 2 Cr 2 O 7 20 mg/kg 358.70 ± 34.56 ∗∗∗ 56.55 ± 3.63 ∗∗∗ 136.30 ± 2.81 ∗∗ 15.70 ± 0.55 ∗∗ 95.67 ± 3.80 ∗
TIE 100 mg/kg + K 2 Cr 2 O 7 255.50 ± 28.47 ∗∗∗ ᵗ 53.33 ± 7.02 ∗∗∗ 129.70 ± 2.29 14.15 ± 0.47 89.33 ± 1.45 
TIE 300 mg/kg + K 2 Cr 2 O 7 160.50 ± 6.84 ∗∗ ᵗᵗᵗ 37.81 ± 2.57 ∗∗∗ ᵗ 128.00 ± 1.73 12.92 ± 0.33 ᵗᵗ 89.50 ± 2.01 
TIE 1000 mg/kg + K 2 Cr 2 O 7 123.70 ± 4.79 ∗ ᵗᵗᵗ 27.81 ± 2.24 ∗∗ ᵗᵗᵗ 124.00 ± 0.86 ᵗ 13.03 ± 0.50 ᵗᵗ 89.67 ± 1.20 
All data are expressed as mean ± S .E.M. ( n = 6), ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 when compared to control group (one-way 
ANOVA followed by Sidak’s post hoc test). ᵗ p < 0.05 and ᵗ ᵗᵗ p < 0.001 when compared to potassium dichromate group (one-way ANOVA 
followed by Sidak’s post hoc test). 
 
 
 
 
 
 
 
 
 
 
 
 
 Acute toxicity of ethanol extract of Terminalia ivorensis in rats 
Administration of the Terminalia ivorensis extract (100 – 5000) mg/kg to Sprague – Dawley rats did not cause adverse
effects on the general behavior of rats (Table S2). No death was recorded after 14 days of continuous observation. The LD 50 
was accordingly estimated to be above 50 0 0 mg/kg body weight in rats. 
Effects of Potassium dichromate on urine output, serum biochemistry and electrolytes of rats pre-treated with Terminalia 
ivorensis extract 
Analyses of 24 – hour urine output showed that Terminalia ivorensis pre-treatment dose dependently prevented decrease
in urine output in rats challenged with a nephrotoxic dose of Potassium dichromate. This protective effect of the extract
was statistically significant at 300 mg ( p < 0.01) and 10 0 0 mg/kg bwt ( p < 0.0 01) ( Fig. 1 ). The extract also protected the
rats against Potassium dichromate-induced rise in serum electrolytes, urea and creatinine. Statistically, there were no signif-
icant differences in serum electrolytes between rats treated with extract plus Potassium dichromate and untreated controls
( Table 1 ). However, unlike serum electrolytes, serum creatinine and urea of Terminalia ivorensis pre-treated animals was
significantly higher than that of the untreated controls. 
Effect Terminalia ivorensis extract pre-treatment on oxidative markers in Sprague-Dawley rats treated with Potassium 
dichromate 
Reduced Glutathione (GSH):- Treatment of rats with Potassium dichromate decreased tissue reduced glutathione (GSH) 
levels. However, pre-treatment of rats with Terminalia ivorensis dose dependently prevented Potassium dichromate-induced 
decrease in tissue reduced glutathione (GSH) levels ( Fig. 2 ). This effects was statistically significant at 300 and 10 0 0 mg/kg.
At these doses of Terminalia ivorensis, there was no statistical significant difference between rats pre-treated with the extract
and toxicant and untreated controls. The lowest dose of Terminalia ivorensis (100 mg/kg) was not effective at protecting
tissue reduced glutathione levels against Potassium dichromate . 
Superoxide dismutase:- Treatment of rats with Potassium dichromate decreased tissue Superoxide dismutase levels. How- 
ever, pre-treatment of rats with Terminalia ivorensis protected enzymes levels against Potassium dichromate-induced damage
( Fig. 3 ). Unlike its effects on reduced glutathione , all doses of Terminalia ivorenses extract significantly protected SOD levels.
There was no statistically significant difference in SOD levels between extract plus toxicant treated rats and the untreated
controls. 
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Fig. 2. Effects of Potassium dichromate (20 mg/kg) and Terminalia ivorensis extract (TIE) (10 0, 30 0, 10 0 0 mg/kg) on GSH levels. ∗∗∗p < 0.001 when com- 
pared to control group (one-way ANOVA followed by Sidak’s post hoc test). ᵗ ᵗᵗ p < 0.001 when compared to K 2 Cr 2 O 7 group (one-way ANOVA followed by 
Sidak’s post hoc test). 
Fig. 3. Effect of Potassium dichromate (20 mg/kg) and Terminalia ivorensis extract (TIE) (10 0, 30 0, 10 0 0 mg/kg) on SOD levels. ∗∗∗p < 0.001 when compared 
to control group (one-way ANOVA followed by Sidak’s post hoc test). ᵗᵗ p < 0.01 and ᵗᵗᵗ p < 0.001 when compared to K 2 Cr 2 O 7 group (one-way ANOVA followed 
by Sidak’s post hoc test). 
Fig. 4. Effects of Potassium dichromate (20 mg/kg) and Terminalia ivorensis extract (TIE) (10 0, 30 0, 10 0 0 mg/kg) on catalase levels. ∗∗∗p < 0.001 as compared 
to the control group (one way ANOVA followed by Sidak’s post hoc test), ᵗᵗᵗ p < 0.001 when compared to K 2 Cr 2 O 7 group (one way ANOVA followed by Sidak’s 
post hoc test). 
 
 
 
 
 Catalase- Similarly, when rats were pre-treated with Terminalia ivorenses extract plus Potassium dichromate, the levels
the heam containing enzyme, catalase, was similar to that of untreated controls. This was statistically significant at 300-
and 10 0 0 mg/kg. The protective effects of the extract on catalase was similar to that on SOD. The lowest dose of the extract
(100 mg/kg) was not effective in protecting tissue catalase against dichromate-induced damage ( Fig. 4 ). 
Malondialdehyde- Treatment of Sprage-Dawley rats with Potassium dichromate resulted in increased lipid peroxidation
of polyunsaturated fatty acids. This was characterised by elevated malondialdehyde in the kidneys of treated rats. However,
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Fig. 5. Effect of Potaasium dichromate (20 mg/kg) and Terminalia ivorensis extract (TIE) (10 0, 30 0, 10 0 0 mg/kg) on MDA levels. ∗p < 0.05 and ∗∗∗p < 0.001 
as compared to the control group (one-way ANOVA followed by Sidak’s post hoc test), ᵗ ᵗ p < 0.01 and ᵗ ᵗᵗ p < 0.001 when compared to Potassium dichromate 
group (one-way ANOVA followed by Sidak’s post hoc test). 
Fig. 6. Effect of Potassium dichromate (20 mg/kg) and Terminalia ivorensis extract (10 0, 30 0, 10 0 0 mg/kg) on MPO levels. ∗p < 0.05 and ∗∗∗p < 0.001 as 
compared to the control group (one-way ANOVA followed by Sidak’s post hoc test), ᵗ ᵗᵗ p < 0.001 when compared to Potassium dichromate group (one-way 
ANOVA followed by Sidak’s post hoc test). 
 
 
 
 
 
 
 
 
 
 
 
 
 when rats were pre-treated with Terminalia ivorenses (100–1000 mg/kg), the extract protected the kidneys against Potassium
dichromate induced lipid peroxidation ( Fig. 5 ). This was characterised by a dose dependent decrease in the tissue levels
of malondialdehyde. At 300 mg/kg and 1000 mg/kg, there was no statistically significant difference in the kidney levels
of Malondialdehyde in extract plus Potassium dichromate treated groups and untreated control group. Although the low
dose of 100 mg/kg of Terminalia ivorenses was effective at protecting the kidneys against toxicant assault, the levels of
Malondialdehyde was significantly higher than that of untreated control. 
Myeloperoxidase- Treatment of Sprage-Dawley rats with Potassium dichromate resulted in increased levels of Myeloper- 
oxidase. Rats pre-treated with the extract expressed decreased levels of Myeloperoxidase when challenge with nephrotoxic
dose of Potassium dichromate. The decrease was dose dependent. At the 300 and 1000 mg/kg, there was no significant
difference in the treated and untreated controls ( Fig. 6 ) 
Histomorphology of kidney sections 
Examination of histopathological sections of kidneys indicated that the control group showed normal renal architecture
characterized by normal glomerular and tubular histology. Potassium dichromate (K 2 Cr 2 O 7 ) treated group showed severe
vacuolar degeneration, glomerular degeneration, tubular necrosis and tubular cast. However, pretreatment of rats with Ter-
minalia ivorensis extract before administration of Potassium dichromate reduced the kidney injury. At 100 mg/kg of extract,
there was a moderate kidney damage characterized by vacuolarization, moderate tubular casts, glomerular degeneration and
necrosis. Whereas extract at 300 and 1000 mg/kg showed mild vacuolarization, glomerular degeneration, tubular casts and
necrosis were observed ( Fig. 7 ). 
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Fig. 7. Effect of Potassium dichromate (K 2 Cr 2 O 7 ; 20 mg/kg) and Terminalia ivorensis extract (TIE10 0, 30 0, 10 0 0 mg/kg bwt) on kidney histomorphology. 
Moderate kidney damage characterized by vacuolarization, moderate tubular casts, glomerular degeneration and necrosis have been indicated with arrows. 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
Medicinal plants play a vital role as first line treatment for various diseases due to their low cost and easy accessibility.
Traditionally, herbalists have used Terminalia ivorensis for ulcers, wounds, diuretic, general body pains, malaria, hemorrhoids
and yellow fever [ 6 , 12 ]. It is also used as timber and antitussive. It has been proven scientifically to possess antihypertensive,
anti-hyperglycemic, antiparasitic, anti-inflammatory and anti-arthritic properties [24–26] . 
Further to our earlier work on the potential nephroprotective activity of ethanol extract of Terminalia ivorensis against
gentamicin-induced renal damage, the present work examined the potential nephroprotective effect of Terminalia ivorensis
on renal oxidative stress and consequent damage induced by Potassium dichromate. In the acute toxicity experiment, no
death was recorded when the extract was administered to rats. The median lethal dose (LD50) was therefore estimated
to be above 50 0 0 mg/kg body weight. As reported previously, any substance with LD 50 beyond 10 0 0 mg/kg body weight
should be considered safe or of low toxicity when orally administered [27] . TIE on this basis can be classified to be of low
toxicity. 
In the present study, administration of Potassium dichromate (20 mg/kg) induced renal dysfunction which was evident
by significant elevation in serum urea, creatinine, electrolytes and decreased body weight with histological damage in the
kidneys. Pre-treatment of rats with Terminalia ivorensis ethanol stem bark extract before induction of nephrotoxicity signif-
icantly increased the urine output when compared to the Potassium dichromate treated group. The observed increase in
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 urine output and alteration of serum electrolytes levels and renal markers may partly explain its purported antihypertensive
property [28] . 
Oxidative stress is strongly linked to many degenerative diseases including kidney damage. The ability of a chemical to
suppress the generation and activity of free radicals can prevent damage to organs and essential biochemical processes [29] .
Superoxide dismutase catalyzes the conversion of superoxide radicals to oxygen and hydrogen peroxide, which is the first
line of defense against reactive oxygen species [ 30 , 31 ]. Catalase then decomposes hydrogen peroxide to water and oxygen
[ 32 , 33 ]. GSH is a soluble tripeptide that acts as an antioxidant and a redox buffer [ 33 , 34 ]. 
During nephrotoxicity, there is a build–up of reactive species, which results in an oxidative degradation of lipids and
other lipid–containing structures in a process termed lipid peroxidation [35] . Lipid peroxidation was quantified in terms of
malondialdehyde (MDA) formed in our study. A high level of MDA indicates high level of cell membrane degradation due
to lipid peroxidation [ 35 , 36 ]. Myeloperoxidase (MPO) is also involved in the development of tissue damage and increased
levels of free MPO are observed in tissues with inflammation [37] . MPO converts hydrogen peroxide and chloride ions into
hypochlorous acid (HOCl) and other highly reactive products [ 38 , 39 ]. 
In this study, nephrotoxicity induced by Potassium dichromate was evident by diminished SOD, GSH and catalase levels
as well as elevated MDA and MPO levels. Extract pre-treated animals showed significantly enhanced superoxide dismutase
(SOD), reduced glutathione (GSH) and catalase activities. The formation of myeloperoxidase and the lipid peroxidation prod-
uct (MDA) were also observed to be significantly reduced in the groups treated with the extract when compared to the
Potassium dichromate group. The activity shown by Terminalia ivorensis ethanolic stem bark extract might be due to its
ability to induce antioxidant enzymes. 
Kidney sections of the control rodents showed normal architecture of tubules while the Potassium dichromate group
showed severe glomerular degeneration, vacuolization, tubular casts and necrosis. However, pre-treatment of rats with 
extract at 100 mg/kg bwt showed a moderate reduction of features of injury in the kidney histology. Additionally, pre-
treatment of rats with extract at 300 and 10 0 0 mg/kg bwt was associated with profound decrease in renal injury similar
to control group. Pre-treatment of rats with extract offered a protective effect against renal damage caused by Potassium
dichromate. 
In conclusion, the ethanolic stem bark extract of Terminalia ivorensis protects against Potassium dichromate – induced
nephrotoxicity in rats. The nephroprotective effect of Terminalia ivorensis could be partly due to obliteration of oxidative
stress by increasing levels of antioxidant enzymes. 
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